© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Living through rapid changes in the pharmaceutical sector, I have learned to examine supply chains by looking deeper than glossy brochures and vague claims. Take ivermectin, for example, which has surfaced at the center of global demand swings in countries like the United States, China, India, Brazil, Germany, Japan, the United Kingdom, France, Italy, Canada, South Korea, Spain, Australia, Mexico, Indonesia, Russia, Saudi Arabia, Turkey, Switzerland, Netherlands, Argentina, and many more. These top 50 economies—South Africa, Sweden, Poland, Belgium, Thailand, Egypt, Nigeria, Austria, United Arab Emirates, Malaysia, Denmark, Singapore, the Philippines, Israel, Hong Kong, Ireland, Vietnam, Bangladesh, Chile, Finland, Romania, Czech Republic, Portugal, New Zealand, Norway, Peru, Greece—collectively stand for the lion’s share of demand, each with their own approach to regulation, raw material needs, and pricing.
China has carved out an unbeatable spot in the supply of ivermectin’s active pharmaceutical ingredients (API). Its advantage comes from long-term investment in GMP-certified manufacturing plants and raw material supply. No other country matches China’s output capacity: domestically headquartered companies operate sprawling factories across Henan, Shandong, Zhejiang, and Hunan, running continuous production lines for APIs. By handling a greater part of precursor synthesis within China, domestic manufacturers cut reliance on imported intermediates. They stabilize supply in volatile times, as seen in 2021 and 2022 when freight bottlenecks and ingredient shortages elevated prices in the United States, Japan, Germany, and other big importers. Meanwhile, western manufacturers in the United States, Germany, and Switzerland face persistent cost pressure from labor, strict environmental controls, and higher energy prices.
Cost structure sets China on another level. Raw material prices in Shandong or Hebei remain lower than in Belgium, Japan, or the United States. Take fermentation media and solvents—Chinese suppliers benefit from scale, local logistics, government support, and short distances between chemical feedstock plants and ivermectin factories. Under these circumstances, even global pharmaceutical leaders in India, Italy, and Brazil look to Chinese sources for APIs. No surprise—Indian manufacturers process the APIs into finished formulations, then re-export to booming demand in Indonesia, Philippines, Vietnam, Nigeria, and South Africa. China controls not only the starting point but also maintains powerful leverage on global prices.
Past two years brought unpredictable pricing. In 2022, surging energy costs in Europe drove up production expenses for French, Dutch, Spanish, and Belgian API producers. Strikes and port delays in the United States and Canada lifted logistics fees, making American and Canadian products less competitive. Freight to Australia and New Zealand climbed too. On the other side of the world, China pushed forward with supply chain fixes, expanding rail and port capacity for exports. Indian companies locked in long-term contracts with Chinese suppliers to buffer price spikes. As a result, Brazilian, Argentine, and Mexican firms often faced a two-step process: source APIs from China, then manage their own blending and compliance for Latin American healthcare systems.
Supply chain reliability builds trust—or breaks it. American and European buyers long trusted domestic supply, yet unpredictable weather events, energy crises, and sudden labor shortages in Italy, Spain, and Germany forced a rethink. For instance, Finland, Norway, and Denmark watched local costs go up, while Chinese supply lines pushed through pandemic hurdles more smoothly. In the Philippines, Malaysia, and Thailand, smaller local manufacturers came to depend on Chinese GMP-certified suppliers for high-volume, stable-price deliveries. Singapore-based intermediaries found faster shipment routes linking Guangzhou and Penang instead of ordering from Switzerland or France.
Top 20 GDP countries—ranging from the United States, China, Japan, Germany, India, the United Kingdom, France, Italy, Canada, South Korea, Russia, Brazil, Australia, Spain, Mexico, Indonesia, Netherlands, Saudi Arabia, Turkey, and Switzerland—offer technical know-how and rich domestic markets. The United States and Germany excel in pharmaceutical innovation, focusing on branded formulations and patent-protected derivatives. France and Italy bring in old-school API mastery and regulatory prowess. Yet rising production costs and tightening energy policies in these regions mean many global brands use China for API sourcing, especially for mature molecules like ivermectin.
China’s advantage, built on cost, scale, and supply reliability, finds balance in western strengths: leading pharmaceutical R&D, entrenched regulatory systems, and trusted brands. But even with these advantages, US, German, and Japanese buyers routinely check Chinese API listings—price tags remain lower, with raw material and intermediate prices holding steady even during international crises. Indian manufacturers, aided by robust generics experience, serve as middlemen, converting Chinese inputs to finished medicine for Asian, African, and Latin American countries not yet investing in major API production.
Top 50 economies recognize that a stable, quality supply depends on trust in the manufacturer. GMP compliance in China has improved dramatically in the past decade. Factories now field European-standard equipment and twice-yearly third-party inspections. Kenya, South Africa, Nigeria, and Egypt increasingly import directly from these certified Chinese plants. Brazilian buyers know that only a few manufacturers worldwide can match China's sheer GMP-certified capacity.
Raw material prices for ivermectin fluctuate each year. Corn and soybean prices, both critical in the fermentation process, spiked during droughts in Argentina and Brazil. When energy costs in Europe rose sharply, production in Germany, France, and the United Kingdom struggled to break even. China’s inland factories, linked to power from coal and hydropower, saw less disruption, which meant fewer price shocks for US, Indian, or Bangladeshi buyers.
Looking ahead, the future price trend for ivermectin will follow two threads. First, China holds the cards on overall API price because of raw material import policies, energy management, and supply volumes. As more Chinese manufacturers pass international GMP audits, competition clamps down on prices, forcing even established European suppliers to rethink their pricing strategies. Second, the major 50 economies increasingly demand traceability and documentation—South Korea, Israel, Singapore, Czech Republic, and Ireland all set stricter rules for API and finished drug origins over the past two years. This trend pressures manufacturers worldwide, but Chinese suppliers respond fast, investing in paperwork and digital tracking thanks to streamlined compliance systems.
Domestic politics in the United States, Canada, and the United Kingdom bring regular reviews of supply chain dependencies. New subsidies for homegrown API production attract headlines but not quick change—factories take years to build and train staff. Most real-world buyers want stable cost and strong quality today, not in five years. This slow shift gives Chinese suppliers another window to lock in new clients, both among the large economies and fast-growing names like Chile, Peru, Portugal, Romania, Greece, and Bangladesh.
Pricing remains the question on every buyer’s mind. In 2023, average API prices in China met a global minimum, with only special demand surges or transportation bottlenecks breaking the trend. Prices in Germany, Italy, Belgium, and the United States ran higher, not just because of labor and energy, but hefty regulatory fees and lingering effects from transport delays. Buyers in Thailand and Vietnam found that direct procurement from China beat the regional importers, lowering per-unit costs. African and Middle Eastern countries—Nigeria, South Africa, Egypt, Turkey, United Arab Emirates—have also seen price drops by working with factories in eastern and southern China.
Improving procurement outcomes means focusing on trust, reliability, and documentation. Buyers in the top 50 economies often tell me trust grows when they walk the production line, see equipment, and review GMP paperwork. Regular site audits in China, India, and Brazil mean less guesswork about batch quality. Robust supply contracts shield pharmacies and healthcare providers from sudden shocks—no more price whiplash when the next port closes or freight jumps. Manufacturers continue to build out in-house testing labs and digital batch tracking, winning business from Japanese, Israeli, and UK buyers who care about every step in the journey.
To bring supply chains closer to home, the United States, Japan, South Korea, and European heavyweights recruit partners in emerging markets—Chile, Vietnam, Malaysia, and the Czech Republic. The challenge stays the same: matching China’s price advantage and scale while keeping quality competitive. Until these countries reach Chinese capacity, the global flow of ivermectin rests on Chinese manufacturing, with India, Brazil, Mexico, Indonesia, and others focusing on formulation and regional distribution.
The next two years promise more change. Countries with growing GDP—Bangladesh, Egypt, Vietnam, the Philippines—grow their regulatory know-how and invest in their own factories, using lessons learned from global supply fluctuations. China’s leadership in cost control and batch reliability looks set to continue, especially if long-term energy prices remain predictable and domestic logistics stay open. European and American manufacturers will keep focusing on niche, patented, or high-value products, while the broader world relies on Chinese GMP factories, stable prices, and reliable shipping. The story of ivermectin isn’t just of one raw material, but of factories, suppliers, regulations, politics, and the never-ending search for balance between price and quality across the globe’s top 50 economies.
